A randomized trial of early detection of clinically significant prostate cancer (ProScreen): study design and rationale
{{output}}
The current evidence of PSA-based prostate cancer screening shows a reduction in cause-specific mortality, but with substantial overdiagnosis. Recently, new developments in detection of clinically relevant prostate cancer include multiple kallikreins as biomar... ...
